On Friday, the European Commission approved the updated corona vaccine from the Mainz-based manufacturer BioNTech and its US partner Pfizer.
It is to be used in the vaccination campaigns of the EU countries this autumn against the dominant variant Omicron XBB.1.5. The Comirnaty vaccine is the third adapted vaccine to be used in the EU. The commission approved the use for adults, children and infants from six months.
The European Medicines Agency (EMA) approved the vaccine earlier this week. She recommends vaccination with the updated vaccine regardless of previous corona vaccinations. BioNTech and Pfizer had announced that they would be able to deliver the vaccine to the EU countries immediately after approval.
Jefferies raises target for BioNTech to $111
Analyst firm Jefferies has raised the price target for BioNTech from $108 to $111 and left the rating on hold. The vaccine specialist is entering a third phase of the study with a HER2 blocker, analyst Akash Tewari wrote in a study published on Friday. While there are differences in the baseline population, similar efficacy with a better safety profile may be achievable compared to the well-known Enhertu.
In NASDAQ trading, BioNTech shares temporarily gained 0.56 percent to $121.61. Meanwhile, Pfizer shares rose 1.12 percent on the NYSE to $35.78.
Brussels / NEW YORK (Reuters / dpa-AFX)
Selected leveraged products on Pfizer Inc.
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on Pfizer Inc.
Leverage must be between 2 and 20